<DOC>
	<DOCNO>NCT02849145</DOCNO>
	<brief_summary>Prospective , open label , monocentric trial evaluation circulate tumor DNA rate blood , curative resection hepatic metastasis uveal melanoma ( HMUM ) post-surgery follow-up</brief_summary>
	<brief_title>Evaluation Interest Circulating Tumor DNA Dosage Patient With Hepatic Metastatic Uveal Melanoma Candidate Complete Resection ( ct DNA R0 )</brief_title>
	<detailed_description>The ct DNA R0 study prospective , open label , monocentric trial . The aim evaluate circulate tumor DNA rate blood , curative resection hepatic metastasis uveal melanoma ( HMUM ) post-surgery follow-up . The patient blood sample surgery post-surgery follow-up . The patient maximum 10 blood sample 2 year follow-up study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<criteria>1 . Aged 18 year old 2 . Patient hepatic injury metastatic uveal melanoma eligible curative surgery ( R0 ) . 3 . No distant metastasis ( CT thoracic abdomino pelvic , bone scan ) .Measurable metastatic disease ( echography , CT and/or MRI , FDGPET , ( fluoro Dglucose integrate computed tomography ) ) . 4 . Patient able stand blood collection . 5 . Patient explanation give consent information sign legal representative . 6 . Patient without social protection / insurance.. 7 . Patient hepatic metastasis unresectable surgery 8 . Patient extrahepatic metastasis . 9 . Person deprive liberty guardianship 10 . Inability submit medical monitoring trial reason geography , social psychological .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Circulating tumor DNA</keyword>
</DOC>